La Jolla Pharmaceutical Quick Ratio (LJPC) starting from the second quarter 2022 to second quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
La Jolla Pharmaceutical Company  (NASDAQ: LJPC)

La Jolla Pharmaceutical's Quick Ratio

LJPC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


La Jolla Pharmaceutical's Cash & cash equivalent grew by 9.21 % in the Q2 2022 sequentially, faster than Current Liabilities, this led to improvement in La Jolla Pharmaceutical's Quick Ratio to 2.95, Quick Ratio remained below La Jolla Pharmaceutical Company average.

Within Biotechnology & Pharmaceuticals industry 125 other companies have achieved higher Quick Ratio than La Jolla Pharmaceutical in second quarter 2022. While Quick Ratio total ranking in the second quarter 2022 has deteriorated compared to the prior quarter from 1293 to 1445.

Explain Quick Ratio?
How much Cash & cash equivalents LJPC´s has?
What are LJPC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LJPC Quick Ratio (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2
Y / Y Current Liabilities Change 3.51 % 39.4 % -14.74 % -10.91 % -10.91 %
Y / Y Cash & cash equivalent Change 6.04 % 15.34 % 119.91 % 68.46 % -35.74 %
Quick Ratio MRQ 2.95 2.78 6.53 2.95 2.88
LJPC's Total Ranking # 1445 # 1293 # 348 # 1337 # 1359
Seq. Current Liabilities Change 2.77 % 124.64 % -54.88 % -0.62 % 38.4 %
Seq. Cash & cash equivalent Change 9.21 % -4.52 % -0.21 % 1.91 % 18.78 %



Quick Ratio second quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 126
Healthcare Sector # 656
Overall Market # 1445


Quick Ratio Statistics
High Average Low
33.52 10.53 0.32
(Sep 30 2014)   (Dec 31 2011)




Financial Statements
La Jolla Pharmaceutical's Current Liabilities $ 16 Millions Visit LJPC's Balance sheet
La Jolla Pharmaceutical's Cash & cash equivalent $ 49 Millions Visit LJPC's Balance sheet
Source of LJPC's Sales Visit LJPC's Sales by Geography


Cumulative La Jolla Pharmaceutical's Quick Ratio

LJPC's Quick Ratio for the trailling 12 Months

LJPC Quick Ratio

 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 3.58 % -1.06 % -16.08 % -32.29 % -31.57 %
Y / Y Cash & cash equivalent TTM Growth 39.81 % 15.63 % -9.95 % -42.28 % -60.88 %
Quick Ratio TTM 3.36 3.35 3.53 2.95 2.49
Total Ranking TTM # 5288 # 5294 # 5301 # 1033 # 5373
Seq. Current Liabilities TTM Growth 1.02 % 9 % -2.39 % -3.62 % -3.51 %
Seq. Cash & cash equivalent TTM Growth 1.51 % 3.33 % 16.69 % 14.24 % -16.05 %

Quick ratio ranking by company, industry and sector >> Back to LJPC Financial Strength Comparisons >> Go to Compare LJPC Quick Ratio to its Competitors

On the trailing twelve months basis LJPC Cash & cash equivalent improved by 6.04 % in Q2 2022 year on year, faster than Current Liabilities, this led to increase in in La Jolla Pharmaceutical's Quick Ratio to 3.36, Quick Ratio remained below LJPC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 192 other companies have achieved higher Quick Ratio than La Jolla Pharmaceutical. While Quick Ratio overall ranking has improved so far to 5288, from total ranking during the twelve months ending first quarter 2022 at 5294.

Explain Quick Ratio?
How much Cash & cash equivalents LJPC´s has?
What are LJPC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 193
Healthcare Sector # 1175
Within the Market # 5288


trailing twelve months Quick Ratio Statistics
High Average Low
14.69 6.46 2.27
(Jun 30 2017)   (Jun 30 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2022 MRQ Cash & cash equivalentJun 30 2022 MRQ Current Liabilities
Quince Therapeutics Inc   8.02 $ 47.736  Millions$ 5.950  Millions
Kalaris Therapeutics Inc   8.00 $ 172.673  Millions$ 21.588  Millions
Surface Oncology Inc   7.94 $ 156.648  Millions$ 19.725  Millions
Senti Biosciences Holdings Inc   7.85 $ 139.800  Millions$ 17.798  Millions
Adverum Biotechnologies Inc   7.70 $ 235.841  Millions$ 30.620  Millions
Solid Biosciences Inc   7.66 $ 162.883  Millions$ 21.273  Millions
Iovance Biotherapeutics inc   7.36 $ 424.458  Millions$ 57.709  Millions
Revolution Medicines Inc   7.26 $ 461.433  Millions$ 63.539  Millions
Inhibikase Therapeutics Inc   7.17 $ 32.212  Millions$ 4.490  Millions
Biomx Inc  7.05 $ 45.745  Millions$ 6.490  Millions
Invivyd Inc   7.00 $ 474.885  Millions$ 67.883  Millions
Cel sci Corporation  6.99 $ 28.074  Millions$ 4.015  Millions
Finch Therapeutics Group Inc   6.89 $ 104.673  Millions$ 15.183  Millions
Autolus Therapeutics Plc  6.87 $ 216.437  Millions$ 31.522  Millions
Imagenebio Inc   6.76 $ 192.810  Millions$ 28.514  Millions
Cognition Therapeutics inc   6.71 $ 45.771  Millions$ 6.818  Millions
C4 Therapeutics Inc   6.67 $ 307.780  Millions$ 46.148  Millions
Dbv Technologies S a   6.59 $ 226.674  Millions$ 34.386  Millions
Armata Pharmaceuticals Inc   6.51 $ 36.978  Millions$ 5.677  Millions
Elevation Oncology inc   6.42 $ 122.542  Millions$ 19.094  Millions
Jounce Therapeutics inc   6.41 $ 148.564  Millions$ 23.195  Millions
Cardiol Therapeutics inc   6.07 $ 45.554  Millions$ 7.510  Millions
Gamida Cell Ltd   5.88 $ 127.333  Millions$ 21.645  Millions
Sqz Biotechnologies Company  5.87 $ 105.561  Millions$ 17.997  Millions
Polarityte Inc   5.84 $ 20.518  Millions$ 3.512  Millions
Vectivbio Holding Ag  5.75 $ 142.144  Millions$ 24.741  Millions
Twist Bioscience Corporation  5.69 $ 527.591  Millions$ 92.686  Millions
Alector Inc   5.41 $ 808.855  Millions$ 149.409  Millions
Tcr2 Therapeutics Inc   5.35 $ 206.238  Millions$ 38.572  Millions
Recursion Pharmaceuticals Inc   5.33 $ 515.436  Millions$ 96.653  Millions

Date modified: 2026-09-08T15:10:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.